In the final couple of years transcatheter aortic valve replacements from Edwards Lifesciences and Medtronic have entered the marketplace and now supply an substitute to surgical treatment for some patients. Now these valves are getting considered for use in patients who have previously undergone surgery but whose bioprosthetic valves have failed.
Despite the fact that surgeons and individuals more and more prefer bioprosthetic valves to mechanical valves, the chief downside to the bioprosthetic valves is that they may possibly eventually deteriorate, which means that much more and a lot more doctors and sufferers will inevitably be faced with the dilemma of how greatest to deal with degenerated valves. Despite the fact that surgical reoperation is regarded the greatest resolution, several sufferers are also old and frail for surgical procedure. Transcatheter aortic valve implantation (TAVI) has been proposed for use in this scenario, however the risks and advantages have not as yet been well defined.
Now, a new study in JAMA supplies info on 459 patients with failed bioprosthetic valves who underwent TAVI with either the Edwards Sapien device or the Medtronic Corevalve device. The investigators in the VIVID (Valve-in-Valve Global Information) Registry report that the death rate was seven.6% at one month and 16.8% at one year. A total of 39.5% of valve failures have been due to stenosis, thirty.3% due to regurgitation, and 30.three% due to a combination of the two. Survival was lowest in the stenosis group and in sufferers with small valves in contrast with sufferers with intermediate-size or massive valves.
Cardiologist David Hillis provided an insightful point of view on this paper:
Inevitably, some recipients of bioprosthetic valves expertise prosthetic valve failure and require some kind of re-do procedure. A repeat surgical AVR carries a considerable chance, because (one) these individuals are typically fairly elderly, and (2) any re-operation possibly can be large-risk (any time 1 cuts into a chest that has been cut on previously, surprises occasionally await — i.e., things is stuck to other stuff that can make the procedure complicated and tough). Bioprosthetic valve failure is not common — but it does take place, notably with prostheses that have been in location for >10-12 many years. Possessing a nonsurgical substitute to repeat AVR is attractive. This registry expertise just concludes that performing TAVI in these men and women is a realistic option. Is it greater than repeat surgical AVR? Naturally, this paper does not answer that query.
In brief, I would phrase this a “feasibility study” — undertaking TAVR on these subjects is possible.”
Research Explores Expanded Use For Edwards" And Medtronic"s New Heart Valves
The approval was primarily based largely on final results from the Excessive Chance Study of the CoreValve U.S. Pivotal Trial. As previously reported right here, the fee of death or major stroke at one 12 months was 25.5%, which was 40.seven% decrease than the prespecified performance goal of 43% (p<0.0001) based mostly on historical requirements. All-result in mortality was 7.9% at 30 days and 24% at one year. Cardiovascular mortality was 7.9% and 17.9%. The fee of key stroke was two.4% at 30 days and 4.1% at 1 yr.